NS Pharma announced that its parent company, Nippon Shinyaku Co., Ltd., has finalized a strategic partnership with Boston Children's Hospital to support the research and development of innovative therapies for rare diseases. The agreement was facilitated by the NS Pharma Innovation Research Partnering (IRP) team, located in Cambridge, MA.
The collaboration will leverage the combined expertise of both organizations in clinical research and pharmaceutical development to bring more treatment options to patients suffering from rare conditions. "Through our strategic alliance with Boston Children's Hospital, the NS Group will continue to apply advanced medical technology in the field of rare diseases," said NS Pharma President Yukiteru Sugiyama. "We are excited about the extensive opportunities for innovation derived from this collaboration and the ability to deliver new therapies to patients suffering from these conditions as soon as possible."
Research Framework and Scope
Under this alliance, Nippon Shinyaku and Boston Children's will align their focus areas, aiming to inspire and support research proposals focused on rare diseases. Nippon Shinyaku will assess the Boston Children's proposals and select those of interest for joint research. The partnership encompasses proposals that may span a range of developmental stages, from early investigations into the biological mechanisms of rare disease, to the identification of possible therapeutic targets, or the generation and validation of new therapeutic entities.
Company Background
NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd., headquartered in Paramus, NJ. Nippon Shinyaku is focused on incurable and rare diseases and is currently marketing Viltepso® (nucleic acid drug), a treatment for Duchenne muscular dystrophy developed in-house, in Japan and the United States. The company's established expertise in rare disease therapeutics positions it well for this collaborative venture with one of the nation's leading pediatric medical centers.
